Home Newsfeeds HTG Molecular Diagnostics Granted Australian Patent Titled ‘METHODS FOR SUBTYPING DIFFUSE LARGE B-CELL LYMPHOMA’

HTG Molecular Diagnostics Granted Australian Patent Titled ‘METHODS FOR SUBTYPING DIFFUSE LARGE B-CELL LYMPHOMA’

http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=2016331058#

byBenzinga Newsdesk

August 3, 2022

1 minute read

http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=2016331058#

Why SeaChange International Is Trading Higher By Around 15%; Here Are 26 Stocks Moving Premarket

By Lisa Levin

September 13, 6:15 AM

Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) rose 41.7% to $2.72 in pre-market trading. Comera Life Sciences Form 4 filing showed multiple insiders purchased 122,600 shares at an average price of $2.03 - $2.07.

ACRX

Movers
News

What’s Going On With AMC Entertainment Stock Wednesday?

By Adam Eckert

May 22, 10:57 AM

Chief Justice Collins J. Seitz Jr. signed a court order on Wednesday affirming a prior ruling to allow AMC to move forward with its stock conversion to AMC Preferred Equity units, or APE units.

AMC

News

Relay Therapeutics Announced Efficacy of RLY-4008, a Highly Selective FGFR2 Inhibitor in Patients with a FGFR2-fusion or Rearrangement FGFR Inhibitor-naïve Cholangiocarcinoma: ReFocus trial

By Charles Gross

September 8, 6:36 AM

https://www.sec.gov/Archives/edgar/data/1812364/000095017022018205/rlay-ex99_1.htm

RLAY

JonesTrading Initiates Coverage On Plus Therapeutics with Buy Rating, Announces Price Target of $5

By Benzinga Newsdesk

October 7, 5:19 AM

JonesTrading analyst Justin Walsh initiates coverage on Plus Therapeutics (NASDAQ:PSTV) with a Buy rating and announces Price Target of $5.

PSTV

HTG Molecular Diagnostics Granted Australian Patent Titled ‘METHODS FOR SUBTYPING DIFFUSE LARGE B-CELL LYMPHOMA’

Related Posts

Why SeaChange International Is Trading Higher By Around 15%; Here Are 26 Stocks Moving Premarket

What’s Going On With AMC Entertainment Stock Wednesday?

Relay Therapeutics Announced Efficacy of RLY-4008, a Highly Selective FGFR2 Inhibitor in Patients with a FGFR2-fusion or Rearrangement FGFR Inhibitor-naïve Cholangiocarcinoma: ReFocus trial

JonesTrading Initiates Coverage On Plus Therapeutics with Buy Rating, Announces Price Target of $5